GlassScriptPhysician profile
Jorge C Suarez Colon
NPI 1356770226
$4,602.85
in general payments reported to CMS, 2019-2025
14 companies · $392 in 2025
The $392 reported for 2025 was more than what 80% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $883 · 2021: $806 · 2022: $702 · 2023: $449 · 2024: $334 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,155.17 | 2019-2025 | Farxiga, Fasenra, Lokelma |
| Janssen Pharmaceuticals, INC | $721.27 | 2019-2025 | Invega Sustenna, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.44 | 2019-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $284.08 | 2020-2023 | Ozempic, Rybelsus |
| Pbg Puerto Rico LLC | $269.87 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $183.80 | 2019-2024 | Eliquis |
| Abbott Laboratories | $113.75 | 2025 | Assurity |
| Biohaven Pharmaceutical Holding Company LTD. | $99.86 | 2022 | |
| Medtronic, INC. | $85.33 | 2025 | Symplicity G3 |
| Eli Lilly Export S.A. Puerto Rico Branch | $60.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $46.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.90 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $28.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $15.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Suarez Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.